Ascentage Pharma Shares Rise Over 4% in Early Trading as Lisaftoclax Receives Breakthrough Therapy Designation from Drug Review Center

Stock News10-21 10:40

Ascentage Pharma (06855) shares rose more than 4% in early trading. As of press time, the stock was up 4.25% at HK$31.86, with a turnover of HK$28.9748 million.

On the news front, Ascentage Pharma announced that its original Class 1 new drug Bcl-2 inhibitor Lisaftoclax® (generic name: lisaftoclax, research code: APG-2575) has been included in the "Breakthrough Therapy Designation" list by the Center for Drug Evaluation of the National Medical Products Administration, for use in combination with acalabrutinib for the treatment of adult patients with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).

Public information shows that Lisaftoclax® is a novel oral selective Bcl-2 inhibitor independently developed by Ascentage Pharma. It was approved for marketing in China in July 2025 for the treatment of adult CLL/SLL patients who have previously received at least one systemic therapy including a BTK inhibitor. It is China's first approved domestically developed original Bcl-2 inhibitor and the world's second approved Bcl-2 inhibitor.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment